Nasus Pharma Ltd. expands intranasal platform as NS002 moves closer to regulatory pathway
Nasus Pharma Ltd. advances NS002 toward pivotal trials with faster epinephrine delivery. Discover what this means for anaphylaxis care.
Pharma & Biotech
Pharma & Biotech
Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start
Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves